3 news items
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
NUVL
16 May 24
to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
NUVL
9 May 24
to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
NUVL
8 Apr 24
of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any
- Prev
- 1
- Next